Published in Antimicrob Agents Chemother on June 01, 1994
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother (1996) 1.42
Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother (1995) 1.38
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother (1994) 1.23
Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res (1994) 1.10
Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry. Antimicrob Agents Chemother (1995) 1.05
Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol (2003) 1.02
Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro. Antimicrob Agents Chemother (1996) 0.99
Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5'-triphosphate as substrate. Nucleic Acids Res (1995) 0.99
Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother (2004) 0.98
Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother (1998) 0.97
Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother (2000) 0.96
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J Virol (1997) 0.95
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother (1998) 0.95
Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues. Biochem J (1997) 0.93
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog. Antimicrob Agents Chemother (2007) 0.91
Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs. Antimicrob Agents Chemother (2001) 0.84
Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrob Agents Chemother (1999) 0.80
In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother (1996) 0.79
Inhibition of replication of hepatitis B virus by cytallene in vitro. Antimicrob Agents Chemother (1997) 0.77
Anti-human immunodeficiency virus activities of nucleosides and nucleotides: correlation with molecular electrostatic potential data. Antimicrob Agents Chemother (2000) 0.75
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer (1976) 14.08
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics (1985) 5.30
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses (1987) 3.67
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 3.52
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother (1992) 3.22
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother (1993) 2.68
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 2.38
LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science (1991) 2.37
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother (1992) 2.17
Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother (1987) 1.86
Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol (1993) 1.56
L-thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth. J Med Chem (1992) 1.41
Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. Proc Natl Acad Sci U S A (1989) 1.40
Nucleoside analogs: similarities and differences. Clin Infect Dis (1993) 1.36
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother (1986) 1.28
Triacontanol and Its Second Messenger 9-beta-l(+)-Adenosine as Plant Growth Substances. Plant Physiol (1991) 1.12
L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J Med Chem (1993) 1.04
Enantiomeric 2',3'-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell cultures. C R Acad Sci III (1994) 0.99
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues. J Med Chem (1987) 0.90
Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents. J Med Chem (1993) 0.87
Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res (1993) 0.85
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines. J Med Chem (1992) 0.82
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects. Hosp Pract (Off Ed) (1992) 0.78
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol (2000) 5.76
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A (1991) 3.82
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 3.52
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.75
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res (1987) 2.71
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother (1997) 2.64
Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1990) 2.53
A radiation hybrid map of the zebrafish genome. Nat Genet (1999) 2.31
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
Evaluation of gene prediction software using a genomic data set: application to Arabidopsis thaliana sequences. Bioinformatics (1999) 2.24
Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion. Hepatology (1993) 2.23
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis (1999) 2.07
alpha-DNA II. Synthesis of unnatural alpha-anomeric oligodeoxyribonucleotides containing the four usual bases and study of their substrate activities for nucleases. Nucleic Acids Res (1987) 2.06
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A (1994) 1.94
High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS (1995) 1.93
Complete nucleotide sequence of the messenger RNA coding for chicken muscle glyceraldehyde-3-phosphate dehydrogenase. Biochem Biophys Res Commun (1984) 1.91
Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol (1987) 1.89
Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother (1987) 1.86
alpha-DNA. I. Synthesis, characterization by high field 1H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide alpha-[d(CpCpTpTpCpC)] with its complement beta-[d(GpGpApApGpG)]. Nucleic Acids Res (1986) 1.83
Host range deletion mutant of vaccinia virus defective in human cells. Virology (1981) 1.81
Assembly of nucleocapsidlike structures in animal cells infected with a vaccinia virus recombinant encoding the measles virus nucleoprotein. J Virol (1991) 1.73
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis (1999) 1.67
Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc Natl Acad Sci U S A (1986) 1.62
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol (1993) 1.56
alpha-DNA. VI: Comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition. Nucleic Acids Res (1987) 1.53
Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother (2000) 1.49
Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother (1982) 1.48
Complementation and genetic linkage between vaccinia virus temperature-sensitive mutants. Virology (1982) 1.45
Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc Natl Acad Sci U S A (1988) 1.43
Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest (1995) 1.42
Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother (1981) 1.41
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother (1995) 1.39
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis (2001) 1.38
Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother (1995) 1.38
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother (1988) 1.36
Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). J Med Chem (1988) 1.33
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother (1999) 1.32
1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J Med Chem (1993) 1.31
A cowpox virus gene required for multiplication in Chinese hamster ovary cells. J Virol (1988) 1.31
Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol (2000) 1.30
In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis (2000) 1.30
Solution-phase synthesis of phosphorothioate oligodeoxynucleosides by the phosphotriester method. Antisense Res Dev (1995) 1.29
Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother (2000) 1.29
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother (1986) 1.28
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis (1999) 1.28
Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A (1996) 1.28
Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J Med Chem (1993) 1.27
Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. J Immunol (1992) 1.27
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS (2000) 1.26
Multiple drug effect analysis with confidence interval. Antiviral Res (1994) 1.26
Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother (2002) 1.26
Mutagenicity of a unique apurinic/apyrimidinic site in mammalian cells. J Mol Biol (1992) 1.25
Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem (1982) 1.25
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1997) 1.24
3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses (1990) 1.24
In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine. Antimicrob Agents Chemother (1993) 1.23
All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat (2013) 1.23
Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother (1994) 1.23
Primary cultures of endothelial cells from the human liver sinusoid are permissive for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.21
High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry (1994) 1.20
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother (2001) 1.20
Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem Pharmacol (1996) 1.20
Sugar modified oligonucleotides. III (1). Synthesis, nuclease resistance and base pairing properties of alpha- and beta-L-octathymidylates. Biochem Biophys Res Commun (1990) 1.18
Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob Agents Chemother (2001) 1.17
Host range restriction of vaccinia virus in Chinese hamster ovary cells: relationship to shutoff of protein synthesis. J Virol (1978) 1.17
Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. Clin Pharmacol Ther (1992) 1.17
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J Med Chem (1989) 1.17
1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. C R Acad Sci III (2000) 1.16
alpha-DNA-V. Parallel annealing, handedness and conformation of the duplex of the unnatural alpha-hexadeoxyribonucleotide alpha-[d(CpApTpGpCpG)] with its beta-complement beta-[d(GpTpApCpGpC)] deduced from high field 1H-NMR. Nucleic Acids Res (1987) 1.16
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother (1989) 1.15
Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells. Biochem Pharmacol (1992) 1.15
Synthesis and biological activities of 5-(hydroxymethyl, azidomethyl, or aminomethyl)-2'-deoxyuridine and related 5'-substituted analogues. J Med Chem (1980) 1.14
Phagocytosis, an unrecognized property of murine endothelial liver cells. Hepatology (1986) 1.14
A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J Med Chem (1995) 1.14
Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. Biochem Pharmacol (1988) 1.14
Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol (1991) 1.14
Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides. Gene (1988) 1.14
Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol (1999) 1.14